Replies to post #12290 on Titan Pharmaceuticals Inc (TTNP)

[turks]

Interesting Doc,right.But I don't think they dropped probuphine for pain it's still there unlike risperidine which you don't see at all.Think they're just waiting for the right time,but it is good news for them to focus on what they have and there bottom line.Just hoping for something positive to happen for a change pps wise,it feels like forever the wait.The new breaburn ceo is focused on sales it seems great news for us.

[Serenity3]

Apple Tree was hoping to IPO & fund Braeburn with other people's money .. their S1, however, laid bare that Braeburn's strategy was not going to generate cash anytime soon... investor's did not take a bite .. so Apple Tree has limited options @this time.. sink > $ into Braeburn or sell assets & fold the company... agree it's generally good news for TTNP.. Braeburn will either sell their probuphine rights or focus resources on making it a success.. still hoping stronger entity buys the entire franchise in order to maximize the drug delivery potential of proneura... as I said before, Apple Tree will find it difficult to compete w/Indivior or Alkemes ... the depot shots are a crowded field in schizophrenia... in addition, it is very difficult to get consents from impaired patients who often do not want any medication at all, much less a long acting shot.. even in a prison setting getting a court order to force a PT even to take oral psychotropic medication requires convincing a judge that the PT's safety depends on him being involuntarily medicated against his will.. court orders, if granted, expire after a year and must again be renewed in court .. in the community, most agencies that I know of will not even attempt to go to court for an involuntary order to medicate .... I suspect Apple Tree did not consult field clinicians when they were hatching their strategic plan.... as for TTNP, right now it too needs cash